The Company expects full year generally accepted accounting principles operating expenses to be between $135 million and $145 million. The Company estimates its cash, cash equivalents, and investments will support operations into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IPSC:
- Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
- IPSC Earnings this Week: How Will it Perform?
- Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
